guest ::
| Home > Publications database > Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells. > print |
| Home > Publications database > Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells. > print |
| 001 | 305504 | ||
| 005 | 20251024115534.0 | ||
| 024 | 7 | _ | |a 10.1182/blood.2024027822 |2 doi |
| 024 | 7 | _ | |a pmid:40749163 |2 pmid |
| 024 | 7 | _ | |a 0006-4971 |2 ISSN |
| 024 | 7 | _ | |a 1528-0020 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-02191 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Pauli, Cornelius |0 P:(DE-He78)09cd3a09acde3c9d99ac67be925b517c |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Disrupting tRNA modifications to target mitochondrial vulnerabilities in drug-resistant leukemia cells. |
| 260 | _ | _ | |a Washington, DC |c 2025 |b American Society of Hematology |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1761225155_2541222 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:A350#LA:A350# / epub |
| 520 | _ | _ | |a Dysregulated RNA modifications contribute to cancer progression and therapy resistance, yet the underlying mechanism often remains unknown. Here, we perform CRISPR-based synthetic lethality screens to systematically explore the role of RNA modifications in mediating resistance to anti-leukaemic drugs. We identify the TRMT5-mediated formation of N1-methylguanosine (m1G) in the tRNA anticodon loop as essential for mediating drug tolerance to cytarabine and venetoclax in acute myeloid leukemia (AML). TRMT5 methylates nearly all mitochondrial and nuclear tRNAs with a guanosine at position 37, but its role in promoting drug tolerance specifically depends on its mitochondrial function. TRMT5 is essential for the dynamic upregulation of mitochondrial mRNA translation and oxidative phosphorylation (OXPHOS), which are critical for sustaining drug tolerance in leukemia cells. This mitochondrial dependency correlates with therapy outcomes in leukemia patients: lower expression of electron transport chain genes is linked to poorer outcomes in a cohort of nearly 100 AML patients undergoing first induction therapy. Finally, we demonstrate that targeted depletion of TRMT5 protein using a conditional degron, in conjunction with cytarabine and venetoclax treatment, synergistically induces cell death in drug-tolerant AML cells. Thus, our study reveals TRMT5 as promising drug target for therapy-resistant leukemia. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Kienhöfer, Michael |0 P:(DE-He78)c724c27d1a864e918fec029b74983a4f |b 1 |e First author |u dkfz |
| 700 | 1 | _ | |a Blank, Maximilian |0 P:(DE-He78)2140ed83f90d7dca2ad207f7f3f9e85c |b 2 |u dkfz |
| 700 | 1 | _ | |a Begik, Oguzhan |b 3 |
| 700 | 1 | _ | |a Rohde, Christian |0 0000-0001-6778-5971 |b 4 |
| 700 | 1 | _ | |a Zimmermann, Sarah |0 P:(DE-He78)bdf74c167c669bda2ac11f901cdeb604 |b 5 |u dkfz |
| 700 | 1 | _ | |a Werner, Laura |b 6 |
| 700 | 1 | _ | |a Heid, Daniel |0 0000-0002-5047-877X |b 7 |
| 700 | 1 | _ | |a Xu, Fu |0 P:(DE-He78)6eb71d7d06e3f5adc6dd806fcb77ac13 |b 8 |u dkfz |
| 700 | 1 | _ | |a Weidenauer, Katharina |b 9 |
| 700 | 1 | _ | |a Delaunay, Sylvain |0 P:(DE-He78)7db81e03313a2df5e17380868363a0d8 |b 10 |u dkfz |
| 700 | 1 | _ | |a Krall, Nadja Katharina |0 P:(DE-He78)d3ba8b1948e4a481b133a0cffea9d621 |b 11 |
| 700 | 1 | _ | |a Trunk, Katrin |0 P:(DE-He78)9d3c5db3c6dffa396b14e1c93baeb7f8 |b 12 |
| 700 | 1 | _ | |a Zhao, Duoduo |0 0000-0002-7602-3597 |b 13 |
| 700 | 1 | _ | |a Zhou, Fengbiao |b 14 |
| 700 | 1 | _ | |a Llovera, Laia |b 15 |
| 700 | 1 | _ | |a Alexane, Ollivier |0 0000-0002-2778-017X |b 16 |
| 700 | 1 | _ | |a Heit-Mondrzyk, Anke |0 P:(DE-He78)a3d2e48d4d32d6b3952996020fe8d1b5 |b 17 |u dkfz |
| 700 | 1 | _ | |a Platzbecker, Uwe |0 0000-0003-1863-3239 |b 18 |
| 700 | 1 | _ | |a Baldus, Claudia D |b 19 |
| 700 | 1 | _ | |a Serve, Hubert |0 0000-0001-8472-5516 |b 20 |
| 700 | 1 | _ | |a Bornhäuser, Martin |b 21 |
| 700 | 1 | _ | |a Vågbø, Cathrine B |b 22 |
| 700 | 1 | _ | |a Benitah, Salvador Aznar |b 23 |
| 700 | 1 | _ | |a Krijgsveld, Jeroen |0 P:(DE-He78)939d5891259c638c1ab053b1456a578c |b 24 |u dkfz |
| 700 | 1 | _ | |a Novoa, Eva Maria |b 25 |
| 700 | 1 | _ | |a Müller-Tidow, Carsten |b 26 |
| 700 | 1 | _ | |a Frye, Michaela |0 P:(DE-He78)78bbb829c94caf04ce9b6fb4a5b13edc |b 27 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1182/blood.2024027822 |g p. blood.2024027822 |0 PERI:(DE-600)1468538-3 |p nn |t Blood |v nn |y 2025 |x 0006-4971 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:305504 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)09cd3a09acde3c9d99ac67be925b517c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)c724c27d1a864e918fec029b74983a4f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)2140ed83f90d7dca2ad207f7f3f9e85c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)bdf74c167c669bda2ac11f901cdeb604 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)6eb71d7d06e3f5adc6dd806fcb77ac13 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)7db81e03313a2df5e17380868363a0d8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)d3ba8b1948e4a481b133a0cffea9d621 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)9d3c5db3c6dffa396b14e1c93baeb7f8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-He78)a3d2e48d4d32d6b3952996020fe8d1b5 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 24 |6 P:(DE-He78)939d5891259c638c1ab053b1456a578c |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 P:(DE-He78)78bbb829c94caf04ce9b6fb4a5b13edc |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BLOOD : 2022 |d 2024-12-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-30 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2024-12-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-30 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-30 |
| 915 | _ | _ | |a IF >= 20 |0 StatID:(DE-HGF)9920 |2 StatID |b BLOOD : 2022 |d 2024-12-30 |
| 920 | 2 | _ | |0 I:(DE-He78)A350-20160331 |k A350 |l A350 Reguläre Mechanismen der Genexpression |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)A350-20160331 |k A350 |l A350 Reguläre Mechanismen der Genexpression |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A350-20160331 |k A350 |l A350 Reguläre Mechanismen der Genexpression |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B230-20160331 |k B230 |l B230 Proteomik von Stammzellen und Krebs |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A350-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B230-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|